Sweden· SE-20161206000172
Trelegy Ellipta 92 mikrogram/55 mikrogram/22 mikrogram Inhalationspulver, avdelad dos
A medicinal product containing umeclidinium bromide + fluticasone furoate + vilanterol, registered in Sweden by GlaxoSmithKline Trading Services Ltd.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Umeclidinium Bromide + Fluticasone Furoate + Vilanterol
- Manufacturer
- GlaxoSmithKline Trading Services Ltd
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20161206000172
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Umeclidinium bromide + fluticasone furoate + vilanterol in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandElebrato ElliptaGlaxoSmithKline Trading Services Limited
- United KingdomTrelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhalerNecessity Supplies Ltd
- SpainELEBRATO ELLIPTA 92 MICROGRAMOS/55 MICROGRAMOS/22 MICROGRAMOS POLVO PARA INHALACION (UNIDOSIS)Glaxosmithkline Trading Services Limited
- CanadaTRELEGY ELLIPTAGLAXOSMITHKLINE INC
- SwitzerlandTrelegy Ellipta, Einzeldosiertes Pulver zur InhalationGlaxoSmithKline AG
- PolandElebrato ElliptaGlaxoSmithKline Trading Services Limited
- NorwayTrelegy ElliptaGlaxoSmithKline Trading Services Limited
- IrelandTrelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elebrato Ellipta, Trelegy Ellipta
- Liechtenstein · Elebrato Ellipta, Trelegy Ellipta
- Norway · Elebrato Ellipta, Trelegy Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb3d3c0a-b3b4-488e-8b14-f09b5b344d7d GET /v1/drugs/fb3d3c0a-b3b4-488e-8b14-f09b5b344d7d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "20161206000172",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20161206000172",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta"
}See everything about umeclidinium bromide + fluticasone furoate + vilanterol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.